GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Bioxyne Ltd (ASX:BXN) » Definitions » Growth Rank

Bioxyne (ASX:BXN) Growth Rank : 0 (As of May. 15, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Bioxyne Growth Rank?

Bioxyne has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.


Bioxyne Growth Rank Related Terms

Thank you for viewing the detailed overview of Bioxyne's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioxyne (ASX:BXN) Business Description

Traded in Other Exchanges
N/A
Address
50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus Fermentum PCC. Some of its products include Breathe life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange etc. It operates in three segments: wholesale sales, Plant based and direct sales. The majority of the revenue is generated from Plant based in the United Kingdom, Europe and Japan.

Bioxyne (ASX:BXN) Headlines

No Headlines